Valeant
FDA approves Valeant eye drug after manufacturing delay
Richard Staines
fda, ophthalmology, regulation, Valeant
0 Comment
Regulator backs potential blockbuster ophthalmology drug
J&J’s psoriasis drug faces crowded market after US approval
Richard Staines
dermatology, Eli Lilly, fda, FDA approvals 2017, Johnson & Johnson, psoriasis, Valeant
0 Comment
J&J taking on next gen drugs from Novartis, Eli Lilly, and Valeant.
Shire plans filing for HAE drug after phase 3 success
Richard Staines
hereditary angioedema, orphan, Rare diseases, Shire, Valeant
0 Comment
Lanadelumab could revolutionise treatment of swelling disease.
Valeant’s Siliq price undercuts rivals to offset black box warning
Richard Staines
dermatology, Eli Lilly, Novartis, pricing, psoriasis, Valeant
0 Comment
Siliq will be cheaper than rivals from Novartis and Eli Lilly.
Drug price controversies hit pharma’s reputation
Richard Staines
Gedeon Richter, Grifols, patient group, pricing, Shire, Valeant
0 Comment
Patient groups slam pharma over drug costs in latest survey.
AstraZeneca/ News/ UK & Europe
AZ looks to file Lynparza in breast cancer
Richard Staines
AstraZeneca, breast cancer, cancer, ovarian cancer, Valeant
0 Comment
UK pharma also gets $130m payment from Valeant.
Valeant’s Siliq approved but suicidal thoughts warning will weigh heavy
Richard Staines
Celgene, Eli Lilly, fda, Novartis, psoriasis, Valeant
0 Comment
But drug will have boxed warning over suicidal ideation.